Frontlight ResearchEarly access
WithdrawnNo phase
Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer
Key facts
- Who runs it
- Ruijin Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- Jun 2019
- Ended
- Mar 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Transanal total mesorectal excision
- Laparoscopic total mesorectal excision
- Record updated
- 17 February 2020
- Why it stopped
- No funding was raised
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- 18 years < age < 80 years
- Body mass index (BMI) <30 kg/m2
- Tumor located in mid and low rectum ( the lower border of the tumor is located distal to the peritoneal reflection)
- Pathological rectal carcinoma
- Clinically diagnosed cT1-3N0-2 M0 lesions according to the 7th Edition of AJCC Cancer Staging Manual with or without neoadjuvant therapeutic history
- Tumor size of 5 cm or less
- ECOG score is 0-1
- ASA score is Ⅰ-Ⅲ
- Informed consent
Who cannot take part
- Intolerance of surgery for severe comorbidities
- Previous abdominal surgery
- History of inflammatory bowel disease
- Severe mental disease
- Emergency operation due to complication (bleeding, perforation or obstruction) caused by rectal cancer
- Requirement of simultaneous surgery for other disease
- Requiring a Mile's procedure
- Fecal incontinence
- Pregnant woman or lactating woman
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is designed to evaluate the short-term and long-term results after transanal total mesorectal excision (TaTME) for the resection of mid and low rectal cancer compared with laparoscopic total mesorectal excision(LaTME).
The 2 groups in the trial
- TaTMETreatment being tested
Patients with mid or low rectal cancer undergo transanal total mesorectal excision.(assisted by laparoscopy to control the IMA)
Treatment: Transanal total mesorectal excision
- LaTMEExisting treatment, for comparison
Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.
Treatment: Laparoscopic total mesorectal excision
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Single-center Prospective Randomized Controlled Study of the Transanal Total Mesorectal Excision Versus Laparoscopic Total Mesorectal Excision in Rectal Cancer
- Record updated
- 17 February 2020